Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Vanessa Moll, MD, PhD Named CMO of Potrero Medical

Dr. Moll brings 20 years of clinical and research experience to the company

Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent the progression of critical conditions such as acute kidney injury (AKI), announced that Vanessa Moll, MD, PhD, FCCM, FASA has joined the executive leadership team as its Chief Medical Officer (CMO).

Dr. Moll brings 20 years of clinical and research experience to the company. She is a board-certified anesthesiologist and intensivist and has worked both in the US and European healthcare systems. She has numerous publications in the field of critical care and anesthesiology and lectures nationally and internationally. Dr. Moll is passionate about building capacity in anesthesiology and critical care and elevating patient care and outcomes globally.

Other Articles

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Eliaz Therapeutics is Raising Capital

The XGAL3® therapeutic apheresis device is the early-mover for the treatment of AKI. ETI has demonstrated significant survival benefits in preclinical models and their prototype device has successfully removed GAL-3 from human blood plasma.

Veranex Announces Acquisition of IMMR

IMMR, a leading preclinical science organization that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators.
spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy